Role of FDG-PET as therapeutic predictive marker of anti-PD-1 antibody in lung cancer

2019 Fiscal Year Final Research Report

• Project/Area Number: 17K10433
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: Saitama Medical University (2018-2019); Gunma University (2017)
• Principal Investigator: Kaira Kyoichi 埼玉医科大学, 医学部, 教授 (40400783)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Keywords: PD-L1 / 免疫療法 / 肺癌 / GLUT1 / HIF-1 / FDG-PET

Outline of Final Research Achievements

In experimental study, cell lines with high and low PD-L1 expression were correlated with the expression of GLUT1 and HIF-1. The trend of high HIF-1 expression was observed in cell line with high PD-L1, compared with that of low PD-L1. The immunohistochemical analysis using 450 tumor specimens with resected lung cancer revealed that the uptake of FDG was closely associated with PD-L1 expression, and there was significantly relationship between PD-L1 expression and GLUT1 and HIF-1. But, there was not association between tumor infiltrative lymphocytes and FDG uptake. Actually, we conducted the exploratory clinical trial to investigate the therapeutic significance of FDG-PET after anti PD-1/PD-L1 antibodies administration in patients with advanced non-small cell lung cancer. This study is ongoing now.

Free Research Field

呼吸器核医学

Academic Significance and Societal Importance of the Research Achievements

抗PD-1・PD-L1抗体の確立したバイオマーカーはなく、現状では腫瘍内PD-L1発現を治療効果予測マーカーの目安にしている。しかし、腫瘍組織内のPD-L1発現を正確に評価することである。そこで、PD-L1発現と関連性のある糖代謝マーカーであるFDG-PETでダイナミックにPD-L1発現の変化をとらえることができれば、免疫療法の効果を予測するのに有望である。本研究はその先駆けになる研究であり、今後の展開が期待されるものと思われる。